NASDAQ · BDX
Healthcare · Medical - Instruments & Supplies
$183.75
Up+$1.00 (+0.55%)
Updated Oct 10, 2026, 8:17 PM
SID Score
5.5/10
Composite research score
Smart Money
47/100
Neutral
Price performance · BDX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
BDX closed at $183.75 after 21 trading sessions, up 3.32% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $181.89 | $183.85 | $181.51 | $183.75 | 1.62M |
| Oct 8, 2026 | $179.76 | $182.76 | $178.90 | $182.75 | 1.52M |
| Oct 7, 2026 | $180.34 | $182.38 | $177.915 | $180.16 | 1.92M |
| Oct 6, 2026 | $183.35 | $187.45 | $180.1219 | $180.30 | 2.05M |
| Oct 5, 2026 | $176.58 | $180.90 | $176.04 | $180.67 | 1.64M |
| Oct 2, 2026 | $177.46 | $178.13 | $175.71 | $176.80 | 1.87M |
| Oct 1, 2026 | $179.11 | $179.665 | $177.02 | $178.07 | 1.29M |
| Sep 30, 2026 | $181.19 | $182.34 | $178.91 | $179.00 | 1.8M |
| Sep 29, 2026 | $182.51 | $182.95 | $180.09 | $181.97 | 1.53M |
| Sep 28, 2026 | $183.07 | $184.34 | $181.95 | $183.83 | 1.89M |
| Sep 25, 2026 | $179.22 | $183.92 | $177.87 | $183.82 | 1.47M |
| Sep 24, 2026 | $182.73 | $183.72 | $178.98 | $179.23 | 1.4M |
| Sep 23, 2026 | $182.10 | $184.37 | $181.31 | $182.52 | 1.02M |
| Sep 22, 2026 | $182.40 | $183.8301 | $180.75 | $183.00 | 1.46M |
| Sep 21, 2026 | $181.25 | $181.53 | $179.98 | $180.70 | 1.46M |
| Sep 18, 2026 | $179.76 | $182.615 | $179.42 | $180.94 | 6.42M |
| Sep 17, 2026 | $182.71 | $184.34 | $181.27 | $181.38 | 1.84M |
| Sep 16, 2026 | $185.18 | $186.27 | $181.29 | $181.85 | 1.73M |
| Sep 15, 2026 | $182.39 | $186.63 | $181.28 | $185.92 | 2.09M |
| Sep 14, 2026 | $180.05 | $183.53 | $179.60 | $182.91 | 1.63M |
| Sep 11, 2026 | $177.60 | $178.30 | $175.20 | $177.85 | 1.58M |
The latest Smart Investors Daily articles mentioning BDX.
Company
Market Activity
Research & News
BDX research
Company profile and research snapshot.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Underweight | — |
| Aug 31, 2026 | B of A Securities | Neutral | — |
| Aug 13, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.
Yahoo · Sep 29, 2026
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 70 years of manufacturing in Sandy, Utah, a key part of the company's U.S. manufacturing network and a critical source of the medical technologies healthcare providers and patients depend on for daily care worldwide.
Yahoo · Sep 28, 2026
Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.
Yahoo · Sep 26, 2026
Waters (NYSE:WAT) President and Chief Executive Officer Udit Batra said the company’s second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses. Speaking at a JPMo
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDX.
